| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
MILFORD, Mass.—SeraCare Life Sciences, which deals in life science products for the diagnostic industry, hasacquired Kirkegaard & Perry Laboratories (KPL), which it describes as "a leadingprovider of antibodies and related reagents for the diagnostic and lifesciences markets."
 
With the acquisition, SeraCare is expanding itsportfolio of products designed to help diagnostic researchers developinnovative in-vitro diagnostic assays through both off-the-shelfproducts and custom antibody design.
 
"The diagnostics industry requires high-quality materials for use inassay design, development of components for regulated kits, andvalidation of these products as they move from the laboratory to theclinic," said Charles Mamrak, CEO of SeraCare. "SeraCare strives tofacilitate its customers' product development efforts, allowingresearchers to focus on the science, specifically the design and launchof cutting-edge new assays. The addition of KPL will enable SeraCare tomore fully meet the needs of these diagnostic researchers, fueling theirinnovation by providing reliable and qualified materials for use inthese assays."
 
KPL's portfolioof products includes immunochemicals for in-vitrodiagnostics, including primary and secondary antibodies as well asreagents and kits targeting ELISA, Western blotting, immunohistology,protein labeling, nucleic acid labeling, sample preparation, proteinpurification and recombinant protein detection and analysis.
 
Theseproducts reportedly "will support SeraCare's expansion from its core strength ofproviding biological products and control materials for infectiousdisease, women's health, and genetic testing into oncology, autoimmune,allergy and companion diagnostics," according to SeraCare
 
"SeraCare is an ideal fit for KPL, bringing two product offeringstogether under one company, and positioning us well to reach a broaderaudience within the diagnostic market," said Albert Perry, president andCEO of KPL. "Our product portfolios, research and development, andmanufacturing expertise are complementary and will enable us to deliver afull suite of capabilities to the diagnostics market."
 
SeraCare secured funding for the acquisition and refinanced its existingdebt with Madison Capital Funding and BB&T Capital Partners, and the company said thisnew financing relationship strengthens SeraCare's capital base forfuture growth both organically and through additional acquisitions.
 
SOURCE: SeraCare news release
 
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue